Ketogenic Diet Cuts Anorexia Symptoms in Pilot Trial, 72% Reach Recovery

Why It Matters

Anorexia nervosa remains a high‑mortality psychiatric disorder with limited effective interventions beyond weight restoration and psychotherapy. The pilot trial suggests that targeting the disorder’s metabolic underpinnings can produce rapid symptom relief without compromising weight, addressing a critical gap in care. If validated, ketogenic therapy could reduce the chronicity and relapse that burden patients, families, and health systems. Beyond individual outcomes, the study signals a paradigm shift toward metabolic psychiatry, where diet and nutrient pathways are leveraged as therapeutic levers. This could spur investment in similar trials for other neuropsychiatric conditions linked to metabolic dysregulation, reshaping research priorities and clinical practice.

Key Takeaways

• Pilot trial enrolled 22 adults with weight‑normalized or mildly underweight anorexia nervosa; 18 (82%) completed the 14‑week ketogenic program.
• 72% of completers reached recovered ranges on EDE‑Q and EDI‑3 eating‑disorder scales by study end.
• All participants showed improvement in Beck Depression Inventory scores, with many entering the normal range.
• No significant weight loss or serious adverse events were reported, demonstrating safety and tolerability.
• Researchers plan a larger, multi‑site trial in 2027 to confirm efficacy and explore neuroimaging biomarkers.

Pulse Analysis

The UC San Diego study arrives at a moment when the mental‑health field is increasingly open to biologically grounded interventions. Historically, anorexia treatment has relied on behavioral and psychopharmacologic strategies, yet relapse rates remain stubbornly high. By reframing the disorder as a neurometabolic condition, the ketogenic approach aligns with emerging research that links altered glucose metabolism and mitochondrial function to psychiatric symptoms.

If the upcoming larger trial validates the pilot’s outcomes, insurers and health‑care providers may begin to reimburse dietary interventions as part of standard care bundles. This could accelerate the development of specialized nutrition clinics staffed by dietitians, psychiatrists, and metabolic specialists, creating a new niche within the wellness industry. Moreover, the trial’s success may encourage pharmaceutical companies to explore adjunctive metabolic agents, potentially leading to combination therapies that pair diet with targeted drugs.

However, scaling the intervention will face practical hurdles. Adherence to a strict macronutrient regimen requires intensive monitoring, which could strain outpatient resources. Additionally, the stigma surrounding high‑fat diets may deter some patients and clinicians. Future research must therefore address implementation pathways, cost‑effectiveness, and patient education to ensure the therapy’s accessibility across diverse populations.